Is It Time To Buy Cambrex Corporation (NYSE:CBM)?
Cambrex Corporation (NYSE:CBM), a life sciences company based in United States, saw a decent share price growth in the teens level on the NYSE over the last few months. As a stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. But what if there is still an opportunity to buy? Let’s take a look at Cambrex’s outlook and value based on the most recent financial data to see if the opportunity still exists. Check out our latest analysis for Cambrex
What’s the opportunity in Cambrex?
The stock seems fairly valued at the moment according to my valuation model. It’s trading around 12% above my intrinsic value, which means if you buy Cambrex today, you’d be paying a relatively reasonable price for it. And if you believe that the stock is really worth $47.32, there’s only an insignificant downside when the price falls to its real value. Is there another opportunity to buy low in the future? Since Cambrex’s share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.
Can we expect growth from Cambrex?
Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. However, with a negative profit growth of -3.48% expected over the next couple of years, near-term growth certainly doesn’t appear to be a driver for a buy decision for Cambrex. This certainty tips the risk-return scale towards higher risk.
What this means for you:
Are you a shareholder? CBM seems fairly priced right now, but given the uncertainty from negative returns in the future, this could be the right time to de-risk your portfolio. Is your current exposure to the stock optimal for your total portfolio? And is the opportunity cost of holding a negative-outlook stock too high? Before you make a decision on the stock, take a look at whether its fundamentals have changed.
Are you a potential investor? If you’ve been keeping tabs on CBM for a while, now may not be the most optimal time to buy, given it is trading around its fair value. The stock appears to be trading at fair value, which means there’s less benefit from mispricing. In addition to this, the negative growth outlook increases the risk of holding the stock. However, there are also other important factors we haven’t considered today, which can help crystalize your views on CBM should the price fluctuate below its true value.
Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Cambrex. You can find everything you need to know about Cambrex in the latest infographic research report. If you are no longer interested in Cambrex, you can use our free platform to see my list of over 50 other stocks with a high growth potential.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.
